nach oben

Breast Cancer Research

Erschienen in:

01.12.2007 | Commentary

Adjuvant endocrine therapy for premenopausal women with early breast cancer

verfasst von: Ting Bao, Nancy E Davidson

Erschienen in: Breast Cancer Research | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896, 104-107. 10.1016/S0140-6736(01)72307-0. 162–165

Clarke MJ: Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ. 1998, 317: 1246-1248.CrossRefPubMedPubMedCentral

Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef

Goldhirsch A, Wood W, Gelber R, Coates AS, Thürlimann B, Senn H-J, Panel Members: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2007, 18: 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed

Robertson JF, Blamey RW: The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer. 2003, 39: 861-869. 10.1016/S0959-8049(02)00810-9.CrossRefPubMed

Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A: Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005, 23: 1736-1750. 10.1200/JCO.2005.11.050.CrossRefPubMed

Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007, 369: 1711-1723. 10.1016/S0140-6736(07)60778-8.CrossRefPubMed

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346: 1616-1622. 10.1056/NEJMoa012158.CrossRefPubMed

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23: 9312-9318. 10.1200/JCO.2005.03.3266.CrossRefPubMed

10.

Stebbing J, Stearns V, Davidson NE: Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics. 2007, 8: 1-3. 10.2217/14622416.8.1.1.CrossRefPubMed

Titel: Adjuvant endocrine therapy for premenopausal women with early breast cancer
verfasst von: Ting Bao
Nancy E Davidson
Publikationsdatum: 01.12.2007
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 6/2007
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1830

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Adjuvant endocrine therapy for premenopausal women with early breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity

The protective side of progesterone

The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer

Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6

Are triple-negative tumours and basal-like breast cancer synonymous?

Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie